267875-30-9

Usage

Uses

Used in Organic Chemistry Synthesis:
2-Cyano-4-methyl-5-nitropyridine is used as a key intermediate for the synthesis of a wide range of valuable compounds in the field of organic chemistry. Its distinctive functional groups, the nitro and cyano groups, provide it with unique reactivity that is harnessed in the creation of diverse chemical products.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Cyano-4-methyl-5-nitropyridine is used as a building block for the development of potential drug candidates. Its structural features allow for the design of molecules with specific biological activities, making it a valuable component in the synthesis of new therapeutic agents.
Used in Agrochemical Industry:
2-Cyano-4-methyl-5-nitropyridine is also employed in the agrochemical industry as a precursor for the synthesis of various agrochemicals, such as pesticides and herbicides. Its reactivity and functional groups enable the production of compounds with targeted effects on pests and weeds, contributing to more effective crop protection strategies.

InChI:InChI=1/C7H5N3O2/c1-5-2-6(3-8)9-4-7(5)10(11)12/h2,4H,1H3

Upstream product

• 557-21-1 dicyanozinc 
• 23056-47-5 2-bromo-4-methyl-5-nitropyridine 
• 557-21-1 zinc(II) cyanide 
• 868551-25-1 4-methyl-5-nitropyridin-2-yl trifluoromethanesulfonate 
• 21901-41-7 2-hydroxy-4-methyl-5-nitropyridine 

Downstream Products

• 868551-26-2 ethyl 4-methyl-5-nitropyridine-2-carboxylate 
• 897733-08-3 5-amino-4-methylpyridine-2-carbonitrile 

Relevant academic research and scientific papers

PLASMA KALLIKREIN INHIBITORS AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES

[Purpose] The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. [Solution] The present invention provides nitrogen-containing fused ring derivatives represented by the following general formula (I) which has a GnRH antagonistic activity, prodrugs, salts, pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the formula (I), rings A and B are independently aryl or heteroaryl; RA and RB are independently halogen, cyano, alkyl, alkylsulfonyl, -OW1, -SW1, -COW2, -NW3W4, -SO2NW3W4, aryl, etc.; RC is H or alkyl; E is oxygen atom, etc.; U is single bond or alkylene; and X is Y, -CO-Y, -SO2-Y -S-(alkylene)-Y, -O-(alkylene)-Y, -SO2-(alkylene)-Y, etc.; Y is Z or amino, etc.; and Z is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.

Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors

HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication. Recently, HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Herein, we report the discovery of azaindole carboxylic aci

Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

The present invention relates to certain substituted pyridinyl and pyrimidinyl derivatives of Fomula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and com

INHIBITORS OF THE HIV INTEGRASE ENZYME

The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.

Azaindoles: Moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors

Starting from a 2-amino-6-methylpyridine P1 group and following a strategy of enlarging it whilst reducing its polarity, we have developed a series of potent, moderately basic azaindoles which are intrinsically much more selective for thrombin versus tryp

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is NY or O; c is CY2or N; d is CY3or N; e is CY4or N; f is CY5or N; g is CY6or N; Y4, Y5, and Y6are independently hydrogen, C1-4alkyl, or halogen; Y1and Y2are independently hydrogen, C1-4alkyl, C3-7cycloalkyl, halogen, NH2, OH or C1-4alkoxy, and Y3is hydrogen, C1-4alkyl, C3-7cycloalkyl, halogen, —CN, NH2, OH or C1-4alkoxy; A is and W, W1, R1, R3, R4, R5, X and Z are defined in the specification.